Joinn Laboratories China Co Ltd

Chart & Performance

D1W1MN

P/E

14.97

P/S

2.50

EPS

0.57

Div Yield, %

0.00%

Shrs. gr., 5y

3.81%

Rev. gr., 5y

42.20%

Revenues

2.38b

+4.78%

Net income

397m

-63.04%

CFO

623m

-35.86%

Dividend

Jun 28, 20240.1933 HKD/sh

Profile

Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics studies, and pharmacology and efficacy studies. The Clinical Trial and Related Services segment provides clinical CRO services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment designs, produces, breeds, and sells research models, non-human primates, and rodents. The company also offers investment management and cell-based assay (CBA) services. Joinn Laboratories(China)Co.,Ltd. was founded in 1995 and is headquartered in Beijing, China.

URL

https://www.joinnlabs.com/

IPO date

Aug 25, 2017

Employees

2,500

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	2,376,487 4.78%	2,267,971 49.54%	1,516,680 40.97%
Cost of revenue	1,561,391	1,356,082	937,819
Unusual Expense (Income)
NOPBT	815,096	911,889	578,861
NOPBT Margin	34.30%	40.21%	38.17%
Operating Taxes	115,398	166,802	85,587
Tax Rate	14.16%	18.29%	14.79%
NOPAT	699,698	745,087	493,273
Net income	396,993 -63.04%	1,074,257 92.71%	557,460 76.96%
Dividends
Dividend yield
Proceeds from repurchase of equity	(113,582)
BB yield	1.18%
Debt
Debt current		27,540	26,195
Long-term debt	83,849	117,055	133,315
Deferred revenue	74,487	80,676	60,844
Other long-term liabilities	1	1
Net debt	(5,079,705)	(3,439,494)	(4,675,567)
Cash flow
Cash from operating activities	622,875	971,066	685,655
CAPEX
Cash from investing activities
Cash from financing activities	(361,678)		5,290,402
FCF	513,132	(281,566)	282,457
Balance
Cash	4,769,756	3,325,318	4,835,077
Long term investments	393,798	258,770
Excess cash	5,044,730	3,470,690	4,759,243
Stockholders' equity	2,915,585	2,644,373	1,517,371
Invested Capital	5,481,868	5,651,908	5,759,517
ROIC	12.57%	13.06%	15.05%
ROCE	9.52%	10.75%	7.90%
EV
Common stock shares outstanding	749,043	537,129	729,386
Price	12.86 -54.94%	28.54 -51.54%	58.89 56.71%
Market cap	9,632,688 -37.16%	15,329,650 -64.31%	42,953,565 83.27%
EV	4,554,707	11,897,321	38,286,220
EBITDA	944,608	1,032,849	675,299
EV/EBITDA	4.82	11.52	56.70
Interest	3,440	3,582	3,962
Interest/NOPBT	0.42%	0.39%	0.68%